Kaposi's Sarcoma

Clinical Trial for Anti-Angiogenic, Immune-Stimulating Drug Seeks Participants

Published in AIDS Weekly, January 8th, 2001

Participants are being sought in Los Angeles, California, to take part in a clinical trial with an experimental cancer drug that can be self-administered as nose drops and has a favorable safety profile.

A total of 200 patients with AIDS-related Kaposi's sarcoma are being sought to participate in a multi-national, Phase III, randomized, placebo-controlled, double-blinded study of IM862, a drug developed by Cytran, Inc. of Kirkland, Washington.

The study will assess the safety and efficacy of IM862 and will be conducted in collaboration with the AIDS Malignancy Consortium of the U.S. National Cancer Institute.

Preclinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-01-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry